BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24577815)

  • 21. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
    Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
    BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer?
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Tech Urol; 2001 Mar; 7(1):12-9. PubMed ID: 11272667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
    J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.
    Jarosek SL; Virnig BA; Chu H; Elliott SP
    Eur Urol; 2015 Feb; 67(2):273-80. PubMed ID: 25217421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
    Abdel-Wahab M; Reis IM; Hamilton K
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
    Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ
    J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The surgical learning curve for prostate cancer control after radical prostatectomy.
    Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
    J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.